




#5

SHEET 1 OF 2

Substitute for form 1449A/PTO	ATTORNEY'S DKT No.	APPLICATION No.
	001560-403	09/869,360
	APPLICANT	
	Harukazu FUKAMI et al	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	FILING DATE	GROUP
	June 28, 2001	To be assigned 1624




U.S. PATENT DOCUMENTS				
Examiner Initials	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication (MM-DD-YYYY)
	Number	Kind Code (if known)		
TNT	5,691,335		FUKAMI et al	11-25-1997
TNT	5,814,631		FUKAMI et al	09-29-1998

FOREIGN PATENT DOCUMENTS						
Examiner Initials	Foreign Patent Document		Country	Date of Publication (MM-DD-YYYY)	Translation	
	Number	Kind Code (if known)			Yes	no
TNT	✓ 97/11941		WO	04-03-1997	Abstract Only	
	✓ 98/18794		WO	05-07-1998	Abstract Only	
	✓ 93/25574		WO	12-23-1993	X	
	✓ 96/04248		WO	02-15-1996	Abstract Only	
	✓ 99/41277		WO	08-19-1999	Abstract Only	
	✓ 93/03625		WO	03-04-1993	X	
	✓ 96/39373		WO	12-12-1996	X	
TNT	✓ 96/33974		WO	10-31-1996	Abstract Only	

NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
TNT	Jozef Oleksyszyn et al, "Irreversible Inhibition of Serine Proteases by Peptide Derivatives of (α-Aminoalkyl)phosphonate Diphenyl Esters" Biochemistry, January 15, 1991, 30, pages 485-493.
	✓ Hidenori Urata et al, "Cloning of the Gene and cDNA for Human Heart Chymase" Biol. Chem., September 15, 1991, Vol. 266, No. 26, pages 17173-17179.
	✓ Margarita Bastos, et al, "Inhibitors of human heart chymase based on a peptide library" Proc. Natl. Acad. Sci., Vol. 92, July 1995, pages 6738-6742.
	✓ Jorma O. Kokkonen, et al, "Role of Mast Cell Proteases and Proteoglycans in Lipoprotein Metabolism" Mast Cell Proteases in Immunology and Biology, pages 257-287, 1995.
TNT	Suguru Nakayama, et al, "Pathophysiological roles of human chymase" Nippon Rinsho, August 1997, 55(08); pages 1903-1908.

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Substitute for form 1449A/PTO	ATTORNEY'S DKT No.	APPLICATION No.
	001560-403	09/869,360
	APPLICANT	
	Harukazu FUKAMI et al	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	FILING DATE	GROUP
	June 28, 2001	To be assigned 1624

	Shinji Takai, et al, "Induction of chymase that forms angiotensin II in the monkey atherosclerotic aorta", FEBS Letters, July 21, 1997, 412(1), pages 86-90.		
	Maki Akasu, et al, "Differences in Tissue Angiotensin II-Forming Pathways by Species and Organs In Vitro" Hypertension, September 1998, 32(3); pages 514-520.		
	Jason L. Johnson, "Activation of Matrix-Degrading Metalloproteinases by Mast Cell Proteases in Atherosclerotic Plaques" Arterioscler Thromb Vasc Biol, November 1998, 18(11), pages 1707-1715.		
	Shlomo Keidar, "Angiotensin, LDL Peroxidation and Atherosclerosis" Life Sciences, 1998, Vol. 63, No. 1, pages 1-11.		
	Masanori Yoshizumi, et al, "Effect of endothelin-1 (1-31) on extracellular signal-regulated kinase and proliferation of human coronary artery smooth muscle cells" British Journal of Pharmacology, 1988), 125, pages 1019-1027.		
	Masanori Yoshizumi, et al, "Endothelin-1-(1-31), a novel vasoactive peptide, increases $[Ca^{2+}]_i$ in human coronary artery smooth muscle cells" European Journal of Pharmacology 348, 1998, pages 305-309.		
TNT	Makoto Ihara, et al, "Increased Chymase-Dependent Angiotensin II Formation in Human Atherosclerotic Aorta" Hypertension, June 1999, 33(6), pages 1399-1405.		
Examiner Signature	<i>Udon</i>	Date Considered	8/30/02

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and \_\_\_\_\_ not considered. Include copy of this form with next communication to applicant. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.



ATTORNEY'S DKT No.

APPLICATION No.

**APPLICANT**

FILING DATE

**GROUP**

U.S. PATENT DOCUMENTS

[illegible]

## FOREIGN PATENT DOCUMENTS

[illegible]

## NON PATENT LITERATURE DOCUMENTS

[illegible]

Examiner Signature		Date Considered	3/27/03
-----------------------	---	--------------------	---------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. **SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.